is tirzepatide considered a glp-1 Associated with Lower POAG, OHT Risk Compared with Other Drugs Researchers Move Closer to Matching

Only ~10% of AbbVies 20252030 sales are at LOE risk (e.g

10.1016/S1360-1385(97)01019-4 Trends Plant Sci

Equally exciting are innovative peptide delivery systems capable of targeting specific cells or tissues, transporting nucleic acids, proteins, radionuclides, or drugs, and enhancing cellular uptake through approaches such as peptidedrug conjugates, cell-penetrating peptides, and functionalized nanoparticles

Dose escalation intensifies this risk

After an initial 36-week period where all participants received Tirzepatide and lost on average about 21% of their body weight, 670 participants were randomized to either continue Tirzepatide or switch to placebo for an additional 52 weeks